 Cardiff Oncology, Inc. Nasdaq: CRDF, a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga-resistant prostate cancer and leukemia, today announced presentation of final results of its Phase 1b study, and preliminary positive data from its Phase 2 study, in relapsed or refractory acute myeloid leukemia AML. The data was presented as a virtual poster presentation at the European Hematology Association EHA annual conference. 